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Fibroblast Growth Factor Receptor 3
Is a Negative Regulator of Bone Growth
Chuxia Deng,* Anthony Wynshaw-Boris,² Fen Zhou, exaggerated lumbar lordosis, and minimal proliferation
of the growth plate cartilage of long bones. MutationsAnn Kuo, and Philip Leder
in several different domains of FGFR-3 cause thanato-Department of Genetics
phoric dysplasia (Tavormina et al., 1995), a common,Harvard Medical School
but more severe and lethal neonatal skeletal dysplasiaHoward Hughes Medical Institute
(Orioli et al., 1979). Further, mutations in the tyrosineBoston, Massachusetts 02115
kinase domain of FGFR-3 cause hypochondroplasia, an
autosomal dominant skeletaldysplasia with skeletal fea-
tures that are similar to, but milder than, those observedSummary
in achondroplasia and thanatophoric dysplasia (Bellus
et al., 1995). Moreover, all of the mutations in achondro-Endochondral ossification is a major mode of bone
plasia, thanatophoric dysplasia, and hypochondroplasiaformation that occurs as chondrocytes undergo prolif-
are dominant missense mutations of the FGFR-3 geneeration, hypertrophy, cell death, and osteoblastic re-
that result in bone dysplasia, suggesting a similar molec-placement. We have identified a role for fibroblast
ular basis for these diseases.growth factor receptor 3 (FGFR-3) in this process by
To understand the role of FGFR-3 in regulating devel-disrupting the murine Fgfr-3 gene to produce severe
opment and to gain an insight into the mechanism(s)and progressive bone dysplasia with enhanced and
underlying these FGFR-3-related inherited disorders ofprolonged endochondral bone growth. This growth is
bone formation, we used homologous recombination inaccompanied by expansion of proliferating and hyper-
embryonic stem (ES) cells (Capecchi, 1989) to createtrophic chondrocytes within the cartilaginous growth
mice that carry a targeted disruption in the Fgfr-3 gene.plate. Thus, FGFR-3 appears to regulate endochondral
Analysis of FGFR-3-deficient mice revealed a remark-ossification by an essentially negative mechanism,
able increase in the length of the vertebral column andlimiting rather than promoting osteogenesis. In light
long bones as a result of enhanced and prolonged boneof these mouse results, certain human disorders, such
growth. Based on this mutant phenotype and in situas achondroplasia, can be interpreted as gain-of-func-
hybridization studies showing that FGFR-3 is expressedtion mutations that activate the fundamentally nega-
in the proliferation zone of chondrocytes of postnataltive growth control exerted by the FGFR-3 kinase.
mice, we suggest that FGFR-3 is essential for restraining
chondrocyte proliferation, thereby inhibitingÐratherIntroduction
than promotingÐbone growth. A comparison between
FGFR-3-deficient mice and their apparent phenotypicFibroblast growth factor receptor 3 (FGFR-3) is one of
human opposites (achondroplasia, thanatophoric dys-four distinct membrane-spanning tyrosine kinases that
plasia, and hypochondroplasia) suggests that theseserve as high affinity receptors for at least nine fibroblast
dominant human diseases may result in varying ligand-growth factors (FGFs) (Basilico and Moscatelli, 1992;
independent activations of FGFR-3.Burgess and Maciag, 1989). While this family of proteins
plays a major role in a variety of developmental pro-
Resultscesses (Erlebacher et al., 1995), in situ hybridization
analyses of developing mouse embryos demonstrate
Targeted Disruption of the Fgfr-3 Genethat FGFR-3 mRNA is expressed at high levels in the
The targeting construct pFGFR-3neo (Figure 1) wascartilage rudiments of a wide variety of bones (Peters
used to disrupt the Fgfr-3 gene. This construct containset al., 1992). This expression pattern suggests a role
8 kb of Fgfr-3 genomic sequence interrupting exon 3for FGFR-3 in bone development. Direct evidence for
with a phosphoglycerate kinase (PGK)neo cassette (Ty-this comes from the discovery that mutations in the
bulewicz et al., 1991). The third exon constitutes a partcoding sequences of the fibroblast growth factor 3 gene
of the Ig2 domain, which is shared by all splice isoforms(FGFR-3) cause bone abnormalities in humans (Rous-
of FGFR-3 mRNA (Chellaiah et al., 1994). Therefore, theseau et al., 1994; Shiang et al., 1994; Tavormina et al.,
PGKneo insertion should truncate the Fgfr-3 coding se-1995). For example, amino acid alterations in the trans-
quence, introducing termination codons in all threemembrane domain of FGFR-3 result in achondroplasia,
frames and creating a null mutation. Isogenic DNA (Dengthe most common form of human dwarfism (Oberklaid
and Capecchi, 1992; teRiele et al., 1992) and two differ-et al., 1979; Rousseau et al., 1994; Shiang et al., 1994).
ent thymidine kinase (TK) genes flanking the Fgfr-3 geneAchondroplastic patients exhibit a characteristic pheno-
were also used to enhance homologous recombinationtype of rhizomelic dwarfism (most pronounced in the
and enrichment (Mansour et al., 1988). Of 48 G418 andproximal portion of the limbs), relative macrocephaly,
FIAU double-resistant ES clones analyzed for homolo-
gous recombination, 20 contained correct targeting
*Present address: Laboratory of Biochemistry and Metabolism, Na- events.
tional Institute of Diabetes, Digestive and Kidney Diseases, National
ES clones heterozygous for the targeted mutation onInstitutes of Health, Bethesda, Maryland 20892
the Fgfr-3 gene were injected into C57BL/6J blasto-²Present address: Laboratory of Genetic Disease Research, Na-
cysts. Germline transmission was obtained from 3/3 ran-tional Center for Human Genome Research, National Institutes of
Health, Bethesda, Maryland 20892 domly chosen clones. As the inserted PGKneo cassette
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liver (two tissues in which FGFR-3 mRNA is normally
expressed) indicated a significant RNA signal in hetero-
zygous Fgfr-3 1/2 mice, but not in their homozygous
Fgfr-3 2/2 littermates (Figure 1C). To study the effect
of the Fgfr-3 mutation on embryonic development, litters
generated by crosses between Fgfr-3 1/2 mice were
dissected and analyzed. Fgfr-3 2/2 homozygous em-
bryos (n 5 20) isolated between embryonic day 12.5
(E12.5) and E18.5 were morphologically normal.
Abnormalities of the Axial and
Appendicular Skeleton
As the postnatal homozygous mice grew, various ab-
normalities in both axial and appendicular skeletons
became apparent. The first visible abnormality (Figure
2A) was observed in the tail such that about half of
Figure 1. Targeted Disruption of the Fgfr-3 Gene the Fgfr-3 2/2 homozygotes developed tail distortions
(A) Targeting vector pFGFR-3neo contains an 8 kb genomic se- (wavy tail) by the second postnatal day (P2). By P3,
quence of the Fgfr-3 genomic locus (not drawn to scale). The tail abnormalities could be seen in all the homozygous
hatched box represents PGKneo inserted at an EcoRI site in the mutant mice. Interestingly, after the first two weeks of
third exon of Fgfr-3, such that 6 kb of the 59 and 2 kb of the 39
life, the tails of the homozygotes seemed togrow consis-sequences flanked the insert. The Fgfr-3 sequences were flanked
tently faster than their heterozygous and wild-type lit-by copies of the HSV-TK genes (shaded boxes). Transcriptional
termate controls (Figures 2B and 2C). As plotted in Fig-directions of neo and TK are indicated by arrows. The targeting
vector was linearized at a unique SalI site prior to electroporation. ure 2C, the lengths of tails of homozygotes and their
Homologous recombination within Fgfr-3 would replace the endog- littermate controls were about the same until P15, after
enous exon 3 with PGKneo. A restriction fragment shift from z30 which the homozygous tails gradually became longer.
kb to 9 kb will be created upon XbaI digestion followed by Southern
When measured at postpartum days 28, 70 and 180,blot using the 32P-labeled 39 probe. Correct targeting events were
tails of homozygotes were of mean lengths ( 6 SD) 8.54confirmed by EcoRV and XbaI digestion followed by Southern blot
6 0.11, 9.67 6 0.21, and 10.67 6 0.65 cm, respectively;using the 32P-labeled 59 probe (data not shown).
(B) Southern blot analysis of DNA isolated from tails of a litter gener- whereas tails of their littermate or age-matched controls
ated by a cross between an Fgfr-3 homozygous mutant female and were of mean lengths 7.98 6 0.2, 8.57 6 0.35 and 8.74
a heterozygous male. Those that showed both 30 and 9 kb XbaI 6 0.23 cm, respectively. This comparison indicated that
fragments were heterozygotes, and those that only had 9 kb frag-
the homozygous mutant tails were longer by 0.56, 1.10ments were homozygotes. Positions of marker fragments at 30 and
and 1.93 cm (mean values), respectively. In contrast to9 kb are indicated. Ev, EcoRV; Sa, SalI; Xb, XbaI; Xh, XhoI.
the homozygous tails which continued to elongate for(C) Northern blot analysis of RNA isolated from a 2-month-old
Fgfr-3 mutant heterozygous mouse (lanes 1 and 2) and a homozy- at least six months, growth of heterozygous and wild
gous littermate (lanes 3 and 4). Lanes 1 and 3 are RNAs isolated type tails could not be measured after the animals
from the brain, and lanes 2 and 4 are RNAs isolated from the liver. reached about three months of age.
About 2 mg polyA RNA was loaded on each lane. An z4 kb mRNA
The most prominent phenotype, however, was a ky-was detected in the heterozygous brain and liver using a 562 bp
phosis that became apparent in most homozygotes atNcoI±EcoRI fragment of the FGFR-3 cDNA (nucleotides 226±788)
P7 and became more severe as the animals grew olderas a probe.
(Figure 2B). Skeletons prepared from Fgfr-3 2/2 homo-
zygotes at P7±P30 indicated that the kyphosis was
caused by bending of the vertebral column, generallyintroduced a new XbaI site, Southern blot analysis re-
vealed a novel 9 kb DNA fragment (replacing a 30 kb at the 4th±6th cervical and the 12th±13th thoracic verte-
brae, rather than a collapse of the vertebral body (Fig-fragment) corresponding to the interrupted gene (Figure
1B). Southern blotting (or polymerase chain reaction ure 3A). Multiple bends along the vertebral column
were observed in skeletons prepared from older mice[PCR] for the presence of the neor gene) indicated that
about 50% of agouti offspring carried the introduced (Figure 3B). Comparison between vertebral columns of
Fgfr-3 2/2 homozygous and wild-type or heterozygousmutation. Phenotypes of FGFR-3-deficient mice from
two of these independently derived ES clones were ana- mice showed that each Fgfr-3 2/2 vertebral body was
proportionately longer than that of the controls (Figureslyzed and found to be identical.
3D and 3F). The total number of vertebrae remained the
same in all mice. In addition to the kyphosis, about halfThe Fgfr-3 Gene is Not Essential for
Embryonic or Postnatal Survival of the Fgfr-3 2/2 homozygotes also developed scoliosis
of varying degrees by the time they reached threeMice heterozygous for the targeted mutation (we shall
refer to such mice as Fgfr-3 1/2) were phenotypically months of age (Figure 3F). Severe kyphoscoliosis was
also observed in about 10% of younger Fgfr-3 2/2 mice.normal. F2 offspring were generated by the intercrossing
of F1 Fgfr-3 1/2 mice. At weaning, mice homozygous These most severely affected mice were usually runted,
had breathing difficulties (apparently secondary to thefor the mutation (Fgfr-3 2/2) were present at a fre-
quency consistent with Mendelian patterns of inheri- skeletal abnormalities), and often died around the time
of weaning. Autopsies revealed that these mice usuallytance. Northern blot analyses of RNA from the brain and
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longer and thicker than those of wild-type and heterozy-
gous controls (Figure 3B). As the mice grew older, the
differences in bone length became more pronounced.
For example, the femurs of Fgfr-3 2/2 homozygous
mice were z20% and z40% longer than wild-type or
heterozygous mice at P90±P100 and P180±P210, re-
spectively. Specifically, the femurs of deficient homo-
zygotes were of mean lengths (6SD) 1.79 6 0.05 cm
(n 5 5) and 2.12 6 0.09 cm (n 5 10) at the earlier and
later time points, respectively; whereas the femurs of
heterozygous or wild-type mice were of mean lengths
(n 5 5) 1.48 6 0.04 and 1.51 6 0.06 at these times. The
mutant humeri were elongated as well with the mean
lengths (6SD) for homozygotes being 1.34 6 0.05 cm
(n 5 5) and 1.44 6 0.05 cm (n 5 6) and the mean length
of control humeri being 1.21 6 0.04 cm (n 5 5) and
1.28 6 0.06 cm (n 5 5) at the respective earlier and later
time points. The heads of mutant femur, tibia, and fibula
were also larger (Figures 3C and 3E).
Histologic Abnormalities
Consistent with the in vivo appearance of the mice,
histologic examination of thecervical, thoracic, and lum-
bar vertebrae did not reveal any abnormalities in the
Fgfr-3 2/2 homozygous mice prior to the third postnatal
day (data not shown). Beginning at P4, however, growth
plates of the vertebrae of the mutant homozygotes were
found to be thicker than those of the control mice. As
shown in Figure 4, comparison between a P20 mutant
homozygote (Figure 4A) and its heterozygous littermate
(Figure 4B) indicates that the height of the cartilaginous
zone is markedly increased in the deficient animal.
Higher power examination (not shown) indicates that
the cellular expansion is largely restricted to the zone
of hypertrophic chondrocytes and is not seen in the
resting or proliferating chondrocytes. Concurrent with
the appearance of leg bowing at approximately two
months of age, expansion of the zone of hypertrophic
chondrocytes was also detected in the growth plates
Figure 2. Tail Distortion, Elongation, and Prolonged Growth in of the knee joint (femur and tibia) of Fgfr-3 2/2 mice.
FGFR-3-Deficient Mice The growth plate of the femur of a homozygous-deficient
(A) FGFR-3-deficient mice with distorted tail phenotype. Animals 1 mouse is shown in Figure 4C as compared with its het-
and 2 were taken from a P3 (postnatal day 3) litter, and animal erozygous littermate control shown in Figure 4D. More-
3 was from a P4 litter. Tail distortions were observed in animals
over, hypertrophic chondrocytes continued to be pro-homozygous for the Fgfr-3 mutation (animals 2 and 3), but not in
duced in the expanded growth plates of mutant micethe wild type (animal 1) and the heterozygote (not shown).
when the animals were six months old, a time when the(B) Kyphosis and long tail phenotypes observed in the Fgfr-3 2/2
mice. Both animals were 2.5-month-old littermates. The phenotypi- control animals show fewÐif anyÐhypertrophic chon-
cally normal Fgfr-3 1/2 heterozygote is shown below; the mutant drocytes (Figure 4E, deficient, and Figure 4F, wild type).
Fgfr-3 2/2 homozygote is shown above. The kyphotic spine is Since hypertrophic chondrocytes are terminally differ-
shown by the arrow.
entiated cells that are derived from the maturation of(C) Growth kinetics of tails of mice homozygous (closed circles) and
proliferating chondrocytes (Gilbert, 1994), expansion ofheterozygous/wild type (open circles) for the Fgfr-3 mutation. Each
the zone of hypertrophic chondrocytes might result frompoint represents the average of at least 10 mice of each type mea-
sured at the age indicated. the enhanced proliferation and maturation of proliferat-
ing chondrocytes. To test this possibility, we stained
epiphysis plates with an antibody that detects the cell
proliferation marker, proliferating cell nuclear antigenhad constricted thoracic cages that were apparently the
result of severe kyphoscoliosis. (PCNA). Dramatic differences in the quantity of prolifer-
ating chondrocytes and/or expression levels of PCNATwo to three months after birth, all the Fgfr-3 2/2
mice began to exhibit a swaying gait abnormality and were detected by comparing femurs from FGFR-3-defi-
cient and control mice, particularly as the mice grewgradually became obviously bowlegged. Skeletal sam-
ples of these mice indicated that the femurs of the older. As shown in Figures 5A and 5B, growth plates
isolated from one-month-old FGFR-3-deficient miceFgfr-3 2/2 homozygotes were bowed and considerably
Cell
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Figure 3. Overgrowth of Axial and Appendic-
ular Skeletons in FGFR-3-Deficient Mice
(A) Skeletons of 15-day-old littermate mice
heterozygous (upper) and homozygous
(lower) for the Fgfr-3 mutation. Arrows point
to kyphotic bends that occurred at the 4th±
6th cervical and the 12th±13th thoracic verte-
brae of the homozygote. (B) Skeletons from
mice heterozygous (upper) and homozygous
(lower) for the Fgfr-3 mutation. The heterozy-
gote was 207 days old; and the homozygote,
190 days old. Arrows point to kyphotic bends
along the vertebral column of the homozy-
gotes. As indicated by triangles, the femurs
of the homozygotic mutant mice were longer
and curved as compared with wild-type con-
trols. Knee joints of these two mice are shown
in (C) (wild type) and (E) (homozygote). The
heads of the femur, tibia, and fibula of the
homozygotes (arrows) are larger than those
of the wild-type mice, (E) and (C), respec-
tively. Thoracic vertebrae isolated from a 60-
day-old wild type (D) and a homozygous lit-
termate (F). The length from the 2nd to the
5th vertebrae of each mouse is indicated by
a line. The ratio of the lengths is 1:1.3 (wild
type:homozygote), and the homozygous and
wild lines are compared in (F). The homozy-
gote also developed kyphoscolisis (F). The
bar, shown in E, is 0.25 cm in (C), (D), (E),
and (F).
contained greater numbers of PCNA-producing cells account for the observation that the mutant interverte-
bral discs appear displaced from the midline in mutantthan those of the corresponding wild-type control. A
direct comparison of 1225 mm2 growth plate fields at mice (compare Figure 6A with 6B). Testing this early
manifestation of the phenotype, we used two bone for-this stage showed that there were (6SD, n 5 3) 9.3 6
1.16 PCNA-labeled nuclei per field in the wild-type mation markers, alkaline phosphatase (a marker for os-
teoblasts) and tartrate-resistant acid phosphatase (agrowth plates as compared with 16.1 6 0.10 in the mu-
tant. Similarly, measurements of the growth plates of marker for osteoclasts) to assess osteogenesis in the
caudal vertebrae isolated from two- and three-day-oldfemurs of two-month-old mutant mice showed 16.6 6
0.07 labeled nuclei per field, whereas wild-type growth mutant mice (Figure 6). Increased alkaline phosphatase
activity in the growth plate cartilage, periosteum, andplates showed only 11.0 6 1.0 labeled nuclei per field.
Moreover, growth plates from the FGFR-3-deficient the ossification center of the Fgfr-3 2/2 mice (Figures
6A and 6B) and increased acid phosphatase stainingmice showed stronger staining by the PCNA antibody
(Figures 5C and 5D). At six months, there is a relative in the space between the degenerating cartilaginous
matrix (Figures 6C and 6D) indicate that increased num-nonuniform expansion of the hypertrophic chondro-
cytes and still a significant number of PCNA-expressing bers of osteoblasts and osteoclasts, respectively, oc-
cupy the growth plate of mutant mice and that loss ofproliferating chondrocytes in the FGFR-3-deficient mice
(10.3 6 2.34), whereas the PCNA-expressing cells in the FGFR-3 results in increased osteogenesis.
Peters et al. (1992) showed that FGFR-3 mRNA iswild-type controls are very sparse (4.3 6 0.77; Figures
5E and 5F). expressed in the pre-bone cartilage rudiments of all
bones during endochondral ossification in the devel-As noted above, the first visible phenotype in homozy-
gous mutant mice is a tail distortion (wavy tail) that oping embryo. Despite this embryonic expression pat-
tern, the Fgfr-3 2/2 mice show no obvious abnor-appears on the second postnatal day and becomes
most pronounced between P5 and P10. Histological malities during embryonic development, suggesting
that expression of FGFR-3 might be redundant at thissections of caudal vertebrae from two- to five-day-old
Fgfr-3 2/2 homozygous mice (Figure 6A) show that point. As noted above, the initial bone abnormalities of
Fgfr-3 2/2 mice appearduring the firstdays of postnataleach of the vertebral bodies is longer than that of its
control littermates (Figure 6B) and that none of the verte- life, suggesting that a requirement for FGFR-3 arises
shortly after birth. We assessed normal FGFR-3 mRNAbral bodies were collapsed (Figures 6A and 6B). These
findings (and those of the kyphoscoliotic thoracic verte- expression in vertebral columns prepared from newborn
(one to seven days old) and juvenile (one and a half tobral column) can be interpreted to suggest that the phe-
notype is caused by bone overgrowth that is no longer two months old) heterozygous or wild-type mice. Exam-
ples of such an analysis indicate that the Fgfr-3 genecoordinated with the growth of the other structural com-
ponents that support and attach to the thoracic and is indeed expressed in thezone of proliferating chondro-
cytes (Figures 7A and 7B [P2] and Figures 7G and 7Hcaudal vertebrae. Such unbalanced overgrowth might
FGFR-3-Deficient Mice
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Figure 4. Expanded Growth Plate Cartilage in FGFR-3-Deficient Mice
(A and B) Sections of the 11th thoracic vertebrae from a P20, Fgfr-3 2/2 homozygous mutant mouse (A) and a heterozygous littermate (B).
RC, resting chondrocytes; PC, proliferating chondrocytes; HC, hypertrophic chondrocytes.
(C and D) Sections of the epiphyseal growth plates of femurs from a P75, Fgfr-3 2/2 homozygous mutant mouse (C) and a heterozygous
littermate (D). The height of the growth plates is indicated by two arrows.
(E and F) Sections of the epiphyseal growth plates of the tibia from a P187, Fgfr-3 2/2 homozygous (E) and a P180, wild-type mouse (F).
BM, bone marrow; TM, trabecular layer of metaphysis. Bar shown in F is 28 mm in (A) and (B); 25 mm in (C)±(F).
[2 months]), the cells that ultimately undergo differentia- suggesting that FGFR-3plays the major role in postnatal
bone development and that there is no compensatorytion to give rise to the hypertrophic chondrocytes that
form the anlage for osteoclast invasion and os- increase in FGFR-1 and FGFR-2 expression in response
to the loss of related FGFR-3.teogenesis.
As noted above, FGF receptors exist as a gene family. To assess the impact of the Fgfr-3 2/2 mutation on
bone formation itself, bone growth and developmentBecause the expression of one member of this family
might influence expression of other members also in- were further assessed using molecular genetic markers
corresponding to the collagens. These genes encodevolved in bone development, we examined the expres-
sion of the Fgfr-1 and Fgfr-2 genes during postnatal major proteins of the cartilage matrices and have been
shown to play an important role in maintaining the mass,bone development using in situ hybridization in both
wild-type and mutant mice. Our results showed that shape, and strength of these tissues (van der Rest and
Garrone, 1991; Erlebacher et al., 1995). Our analysesFgfr-1 is expressed in the hypertrophic chondrocytes
of the vertebral column isolated from P2 wild-type mice indicated that the expression patterns of these genes
are essentially the same in Fgfr-3 2/2 and wild-type(Figures 7I and 7J). Loss of FGFR-3 does not cause an
obvious change in expression pattern of the Fgfr-1 gene mice, only proportionately expanded to account for in-
creased bone size in Fgfr-3 2/2 mice. For example,(data not shown). In older mice (P60), Fgfr-1 expression
cannot be detected in the epiphyseal growth plate using collagen X is largely expressed in hypertrophic chondro-
cytes and serves as a marker for these cells (Figure 7C).the same probe (data not shown). We also fail to detect
FGFR-2 mRNA at both of these timepoints (not shown), In FGFR-3-deficient mice, a wider hybridization band
Cell
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Figure 5. Increased Numbers of Proliferat-
ing Chondrocytes as Measured by Elevated
Expression of Proliferating Cell Nuclear Anti-
gen in the Epiphyseal GrowthPlates of FGFR-
3-Deficient Mice
Sections of the epiphyseal growth plates of
femurs from Fgfr-3 2/2 homozygous mutant
(B, D, and F) and wild-type control mice (A,
C, and E). The growth plates are taken from
one-month- (A and B), two-month- (C and D),
and six-month- (E and F) old mice, respec-
tively. The height of the growth plates is indi-
cated by two arrows. PC, proliferating chon-
drocytes; HC, hypertrophic chondrocytes.
BM, bone marrow. The mutant and wild-type
growth plates of each time point were treated
under identical conditions so that the relative
levels of PCNA can be compared. Note, bone
marrow is also stained in all sections. A com-
parison between the proliferating chondro-
cytes and bone marrow is helpful to judge the
staining intensities. PCNA-producing nuclei
were counted in three 1225 mm2 square fields
for each sample as indicated in the text (see
Results). The bar shown in (F) is 35 mm in
each panel.
corresponding to collagen X mRNA expression is ob- appear debilitated by comparison with their heterozy-
gous and wild-type littermate controls. Also as notedserved and is proportional to the increased size of the
zone of the hypertrophic chondrocytes seen in these above, mice that showed particularly severe kyphoscoli-
osis were also severely runted. While it is possible thatmutant mice (Figure 7D). Appropriate expression of col-
lagen X suggests that these chondrocytes are function- this debilitation is a consequence of a primary mitogenic
function of FGFR-3, it is more likely to be a consequenceing normally. We have also examined expression of col-
lagen I and bone morphogenetic proteins 2, 4, and 6 of the skeletal anomalies associated with FGFR-3-defi-
ciency. The severe kyphoscoliosis we observe clearlyand found no differences between mice heterozygous
and homozygous for the targeted mutation (data not impedes rib cage excursion and must diminish respira-
tory volume.shown).
Other Potential Effects of the Fgfr-3 Mutation
While FGFR-3 is expressed prominently in the cartilage Discussion
rudiments of the developing embryo, it is also expressed
diffusely in the developing central nervous system, in There are two fundamental mechanisms of bone ossifi-
cation in the vertebrate: intramembranous and endo-the developing lens, and in the differentiating hair cells
of the cochlear duct (Peters et al., 1992). On simple chondral (see review Gilbert, 1994). The former is princi-
pally involved in the formation of the flat bones of theobservation, Fgfr-3 2/2 mice appear to have no gross
neurologic deficits. At autopsy, aside from the bone skull in which mesenchymal cells directly develop into
osteoblasts that, in turn, secrete the proteins of the bonemalformations and the structural anomalies they induce,
no other gross or histological abnormalities were ob- matrix, ultimately resulting in calcification and bone for-
mation. The latter, accounting for the formation of mostserved. In particular, histologic examination of the brain,
eye, testis, muscle, blood, and flat bones of the skull of the bones of the organism, involves a two-stage pro-
cess whereby cartilage-forming cells, chondrocytes,revealed no obvious abnormalities (data not shown).
Nonetheless, as noted above, most Fgfr-3 2/2 mice form a prebone cartilaginous primordia or template in
FGFR-3-Deficient Mice
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Figure 6. Enhanced Ossification in the FGFR-3-deficient Mice
(A and B) Sections of the 13th caudal vertebrae from a P2,
Fgfr-3 2/2 homozygous mouse (A) and a heterozygote littermate
(B). Both sections were stained by alkaline phosphatase to show
ossification (red). Arrows indicate the intervertebral discs. Notice
the intervertebral disc in the Fgfr-3 2/2 mouse is lateral to the
midline. RC, resting chondrocytes; PC, proliferating chondrocytes;
HC, hypertrophic chondrocytes. BM, bone marrow. Arrowheads in-
dicate the periosteum.
(C and D) Sections of the 15th caudal vertebrae from a P2 homozy-
gous mutant mouse (C) and a heterozygote littermate (D). Both
sections were stained by acid phosphatase to show osteoclasts
(arrowheads). Bar in (D) equals 25 mm in each panel.
which osteoblasts differentiate and continue the pro-
cess of ossification. It has for some time been clear that Figure 7. Assessment of FGFR-1, FGFR-3, or Type X Collagen
mRNAs in the Growth Plates of Fgfr-3 2/2 Homozygous,this process is influenced by a wide variety of effectors
Fgfr-3 1/2 Heterozygous, and Wild-Type Miceincluding bone morphogenic proteins (BMPs) (Lyons et
(A), (B), (C), and (E) show adjacent sections of the 15th caudal verte-al., 1991; Rosen and Thies, 1992), collagens (van der
brae from a two-day-old Fgfr-3 1/2 heterozygous mouse. (A) is aRest and Garrone, 1991; Jacenko et al., 1993; Erlebacher
light-field view, while (B), (C), and (E) are dark-field views showing
et al., 1995; Li et al., 1995), growth hormone and insulin- hybridizations using a Fgfr-3 antisense (B), Fgfr-3 sense (E), and
like growth factors and their receptors (Nilsson et al., type X collagen antisense (C) probes, respectively. (D) and (F) show
1986; Baker et al., 1993), and other peptide hormones adjacent sections of the 15th caudal vertebrae from a Fgfr-3 2/2
homozygous littermate. (D) Dark field showing a section hybridized(Amizuka et al., 1994; Karaplis et al., 1994). Dietary fac-
with the collagen type X antisense probe. (F) Light field. (G) and (H)tors also play a role.
are adjacent sections of an epiphyseal growth plate from a two-Although we have a descriptive notion of how endo-
month-old wild-type mouse. (G) is a light-field view, while (H) is a
chondral ossification occurs (chondrocytes develop dark-field view showing hybridization with an Fgfr-3 antisense
from mesenchymal cells, proliferate, undergo hypertro- probe. Arrows in (A), (B), (G), and (H) point to proliferating chondro-
phy, begin to calcify, undergo a program of cell death, cytes. At both time points, FGFR-3 mRNA is detected exclusively
in the zone of proliferating chondrocytes. Arrows in (C) and (D)and are replaced by osteoblasts), we are only now begin-
indicate the zone of hypertrophic chondrocytes. (I) and (J) are light-ning to understand how the above-noted elements and
field anddark-field views, respectively, of sections of a caudal verte-the genes that encode them influence this process at
bra from a P2 wild-type mouse. (J) shows a section hybridized with
the molecular level (reviewed in Erlebacher et al., 1995). an Fgfr-1 antisense probe. Arrows indicate hypotrophic chondro-
Formation of bone is of particular interest in that all cytes. Bar shown in (J) equals 36 mm in all panels.
bone tissue must move through a common process of
developmentwhile also being influenced by local factors
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that give each bone its unique architecture. Several mu- suggests that either FGFR-3 is not functional in all the
rine mutations that affect specific bone elements sug- embryonic organs in which it is expressed, orÐif it isÐ
gest that this is the case (Kingsley et al., 1992; Storm that its function is replaced by other signaling elements,
et al., 1994). Further to the process of localized bone possibly other members of the FGF receptor family.
development, the correlation of several dominantly in- Early in situ hybridization studies, now worth reexam-
herited skeletal dysplasias with specific human muta- ining, indicated a nonoverlapping expression pattern for
tions in FGFR-1, -2, or -3 strongly implicate the FGF members of the FGF receptor family during embryo-
family in this process (see below and reviewed in genesis. For example, FGFR-1 is expressed almost ex-
Muenke and Schell, 1995). clusively in mesenchyme;FGFR-2 is expressed predom-
In general, FGFs are thought to deliver a mitogenic inantly in epithelium (Orr-Urtreger et al., 1991) and
signal in a variety of cells, but more recent evidence FGFR-4 expression is restricted to epithelium of the
suggests that they can be involved in differentiation, cell embryonic gut, to myotomes, and to specific groups of
motility, and survival (reviewed in Mason, 1994). Given skeletal muscles (Stark et al., 1991). It is possible that
that previous studies in mouse embryos indicated that there is a feedback control mechanism in which loss
FGFR-1, -2, and -3 are expressed in prebone cartilage of one element of this regulatory pathway induces its
(Peters et al., 1992, 1993) and that human skeletal dys- replacement by a serviceable substitute. Obviously, de-
plasias have been found associated with mutations in tailed studies of the embryogenesis of FGFR-3-deficient
genes corresponding to these receptors, the question mice and other FGF receptor±deficient mice will resolve
arises as to how the FGF receptors influence bone this question.
growth. As discussed below, this question is not easily
answered from the human mutations since they are Implications for the Molecular Consequences
largely dominant and, given the suspected homo- or of FGFR-3 Mutations in Humans
heterodimeric structure of the FGF receptors, could be Missense mutations in various domains of FGFR-3 have
the result of gain-of-function/activation or loss-of-func- been reported to cause the dominant heritable human
tion/dominant-negative mutations. skeletal dysplasias: achondroplasia, thanatophoric dys-
The question is best addressed in terms of FGFR-3 plasia (types I and II), and hypochondroplasia (Rousseau
in the mouse by creating a recessive, loss-of-function et al., 1994, 1995; Shiang et al., 1994; Bellus et al., 1995;
mutation and assessing the phenotype. In doing this,
Tavormina et al., 1995). (Recall that hypochondroplasia
we first note that the skeletal defects produced by this
is a milder form of dwarfism and is similar to achondro-
loss-of-function mutation are restricted to bones that
plasia.) Assuming that we can make a useful comparison
arise by endochonral ossification: the vertebral bodies,
between species, the Fgfr-3 2/2 mice we have gener-
the tail, and the long bones, particularly the femur (Fig-
ated display a recessive phenotype that is, in several
ures 2±4). Dominant mutations that occur in the human
respects, opposite to (if not just different from) thoseFGFR-3 gene principally (but not exclusively) affect
observed in individuals with achondroplasia and thana-bones that arise by endochonral ossification, whereas
tophoric dysplasia. The most striking contrasts in phe-dominant mutations that involve the human FGFR-1 and
notype are apparent in the height of the vertebral col-FGFR-2 genes principally induce craniosynostosis and
umns, length of proximal limbs, and the proliferationfacial abnormalities that involve bones arising by intra-
of growth plate chondrocytes. Owing to the dominantmembranous ossification. Second, the bone defect pro-
nature of the human mutations and the recessive (loss-duced by the loss-of-function mutation in Fgfr-3 does
of-function) nature of the mouse mutation, a comparisonnot restrict bone growth (the principal effect seen in
of these phenotypes should provide some clue as tothe dominant dwarf mutations of the FGFR-3 gene in
the molecular and cellular mechanism(s) that underliehumans) but induces an overgrowthof theendochondral
these anomalies and the mode of action of FGFR-3.skeleton. Moreover, the bone overgrowth, at least as
Theoretically, a dominant phenotype can be causedmeasured in the caudal vertebrae (Figure 2) and femur
either by a gain-of-function mutation, a loss-of-function(Figure 3), is both accelerated and prolonged. These
mutation manifesting the effects of haploinsufficiencyresults therefore suggest that FGFR-3 is normally a neg-
in the heterozygous state, or a dominant-negative muta-ative regulator of bone growth.
tion interfering with the action of the product of theExpression of a gene in a tissue in which there is no
functional allele. Again, assuming that we can makeapparent phenotype is generally ascribed to redun-
useful comparisons between species, mice with onlydancy of the gene or to insensitivity of the assay. The
one functional Fgfr-3 allele are phenotypically normaleffect of the targeted disruption of the Fgfr-3 gene ap-
and fail to show phenotypes resembling achondroplasiapears to primarily involve postnatal bone growth and
(dwarfism) or thanatophoric dysplasia, thus ruling outdevelopment. However, Fgfr-3 is also expressed in em-
the possibility of haploinsufficiency. This is consistentbryonic bone primordia, in the developing central ner-
with the observation that the heterozygous deletion ofvous system, lens,and cochlear duct (Peters et al., 1993)
the FGFR-3 gene in the human Wolf±Hirschhorn syn-and at varying levels in liver, spleen, lung, intestine,
drome does not result in any type of skeletal dysplasiakidney, and skin (Partanen et al., 1991; Tavormina et al.,
(Chitayat et al., 1995). Moreover, the fact that mice ho-1995). This expression pattern suggests a wider po-
mozygous for the targeted mutation of the Fgfr-3 genetential role for FGFR-3 than is apparent from the
fail to show the dwarfism phenotypes associated withFgfr-3 2/2 phenotype in which the most obvious patho-
achondroplasia and thanatophoric dysplasia suggestsgenic effects can be related to the skeletal abnormali-
that the human diseases are not a consequence of loss-ties. Leaving aside the possibility that we have over-
looked subtle developmental abnormalities, this result of-function of FGFR-3. This further argues against the
FGFR-3-Deficient Mice
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possibility that either human disease is caused by a this is reasonable, we suppose that the effects of these
opposite actions are mediated by the same group ofdominant-negative effect, since such an effect would
result in the loss of FGFR-3 function. Of course, a caveat downstream effectors that are either shut off or turned
on by these two opposite signals.must be raised with respect to this last issue in that a
dominant-negative mutation in the FGFR-3 gene may
negatively influence other gene products and thus have
Experimental Procedures
a broader or different phenotype than that observed in
a clear loss-of-function mutation. Targeting Vector
Recombinant phages containing genomic DNA of the Fgfr-3 locusBased on the current knowledge of signal transduc-
were isolated from a 129-mouse library (Stratagene) by using ation by the FGF pathway, activation of FGF receptors
mouse FGFR-3 cDNA probe (Ornitz and Leder, 1992). An 8 kb HindIIIoccurs only after ligand binding (Mason, 1994). The fact
to SalI (the SalI site is from polylinker of the phage vector) fragment
that the recessive loss-of-function mutation produces was subcloned into pBluescript IIKS(1) (Stratagene) followed by the
a phenotype in mice which appears opposite to that insertion of the PGKneo gene (Tybulewicz et al., 1991) at a unique
of achondroplasia or thanatophoric dysplasia suggests EcoRI site (nucleotides 788±793) in the third exon. Two different
thymidine kinase genes, TK-1 and TK-2 (Mansour et al., 1988), werethat the human mutation may have resulted from a con-
then placed at the 59 and 39 ends of the genomic DNA, respectivelystitutive activation (or ligand-independent activation) of
(Figure 1A). The targeting vector was partially sequenced to confirmthe receptor. Constitutive activation caused by mis-
the predicted disruption due to the neo insertion (data not shown).sense mutations has been reported in several growth
factor receptors (Bargmann et al., 1986; Longo et al.,
Homologous Recombination in ES Cells1993). For example, a single amino substitution of Val
and Generation of Germline Chimerasto Glu in the transmembrane domain of the c-neu onco-
A newly established ES cell line (derived from a 129/SvEvTacfBR
gene results in activation of the tyrosine kinase function mouse), TC1, was transfected with SalI-digested pFGFR-3neo and
(Bargmann et al., 1986). A similar situation is created in selected with G418 and FIAU. The culture, electroporation, and se-
the insulin receptor when a Val in the transmembrane lection of TC1 cells were carried out as described (Deng et al., 1994).
ES cell colonies that were resistant to both G418 and FIAU weredomain is substituted with a negatively charged amino
analyzed by Southern blotting for homologous recombinationacid, Asp (Longo et al., 1993).
events within the fgf-3 locus. Genomic DNAs from these clones andIf the normal role of FGFR-3 is to modulate prolifera-
the parental TC1 cell line were digested with XbaI, and then probed
tion of chondrocytes and repress their maturation, it is with the 59 and 39 fragments specific to the Fgfr-3 sequence (Fig-
conceivable that a constitutive repression would abnor- ure 1). ES cells heterozygous for the targeted mutation were mi-
mally impede chondrocyte maturation and induce bone croinjected into C57BL/6 blastocysts to obtain germline trans-
mission.dysplasia. The true situation is likely to be much more
Genotype Analysiscomplicated than this. For example, a dosage effect was
Genotypes were determined by Southern blotting or PCR. For PCRobserved among different mutations within the different
analysis, the wild Fgfr-3 allele was detected using a 59 oligonucleo-domains of the FGFR-3 gene (Shiang et al., 1994; Tavor-
tide (59 GGCTCCTTATTGGACTCGC 39) and a 39 oligonucleotide (59
mina et al., 1995). The transmembrane mutations that TCGGAGGGTACCACACTTTC 39). This primer pair flanks the
result in achondroplasia seem to be weaker alleles than PGKneo insertion site and amplifies a 308 bp fragment from the wild-
the mutant alleles that generate the thanatophoric dys- type Fgfr-3 gene. Theoretically, these primers could also amplify
an z2100 bp fragment from the Fgfr-32 allele in heterozygous orplasia phenotype, a notion supported by the observation
homozygous embryos. However, under our PCR conditions, thethat two copies of the achondroplasia allele produce a
amplification of this fragment was inefficient and not easily visual-homozygous phenotype similar to that of thanatophoric
ized by ethidium staining. DNA was also amplified using neo primers
dysplasia. Even among thanatophoric dysplasia pa- to detect the neo gene in the mutant Fgfr-3 allele as described
tients, different mutations result in two apparent types of previously (Deng et al., 1994). In this case, a 431 bp fragment was
disease (Rousseau et al., 1995; Tavormina et al., 1995). detected in mice heterozygous or homozygous for the human
Fgfr-3 allele, while no signal was detected in wild-type mice.Moreover, the compound heterozygote formed between
achondroplasia and hypochondroplasia alleles (the lat-
ter being the weakest allele of the FGFR-3 mutations) Skeleton Staining
Animals were euthanized by asphyxiation in CO2. After removinghad a stronger phenotype than that seen in the presence
the skins, the carcasses were eviscerated, fixed in 95% ethanol,of each allele alone (McKusick et al., 1973). These obser-
stained with Alizarin red S and Alcian blue, cleared by KOH treat-vations could be accommodated by assuming that the
ment, and stored in glycerol as described (McLeod, 1980).
quantitative difference in phenotype could be due to
alleles with varying degrees of ligand-independent acti-
Histology, Enzymatic and Antibody Stainingvation generated by missense mutations occurring at
To carry out histological studies, bones were fixed in Bouin's fixativedifferent domains within the receptor.
(Sigma) at 48C overnight, dehydrated through a graded alcohol se-
In view of the foregoing, we propose that a normal ries, and embedded in paraffin. Sections of 6±8 mm were prepared
function of FGFR-3 is to limit rather than promote os- and stained with Harris hematoxylin and eosin according to standard
teogenesis. Loss of FGFR-3 results in both accelerated procedures. For endogenous alkaline phosphatase and tartrate-
resistant acid phosphatase staining, tails of P2 and P3 mice wereand prolonged bone growth. Roughly compared, human
fixed for 48 hr in 100% ethanol containing 3.2% (w/v) polyvinylpyrrol-achondroplasia and thanatophoric dysplasia patients
idone and 20% dimethylsulfoxide. The samples were then embed-that bear dominant mutations in the FGFR-3 gene dis-
ded in paraffin and sectioned. The substrate for alkaline phospha-
play a dwarf phenotype that is opposite to that of our tase was purchased from Vector laboratory, and the reagents for
FGFR-3-deficient mice. We, therefore, suggest that they acid phosphatase were purchased from Sigma (Procedure No. 387).
are caused by an opposite mechanism; i.e., a constitu- PCNA antibody (PC 10) was purchased from Signet. The detections
were carried out as recommended by the manufacturers.tive or ligand-independent activation of the receptor. If
Cell
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Northern Blots Deng, C., and Capecchi, M.R. (1992). Reexamination of gene tar-
geting frequency as a function of the extent of homology betweenRNA was isolated from tissues using RNA TeT-60 based on the
protocol suggested by the manufacturer (Tel-Test ªB,º Inc.). PolyA the targeting vector and the target locus. Mol. Cell. Biol. 12, 3365±
3371.RNA was prepared using a kit purchased from Pharmacia. About 2
mg of polyA RNA from each sample was electrophoresed on a 1% Deng, C., Wynshaw-Boris, A., Shen, M., Daugherty, C., Ornitz, D.M.,
agarose gel and transferred to a Gene-Screen filter. The filter was and Leder, P. (1994). Murine FGFR-1 is required for early post-
then hybridized with a 32P-labeled Fgfr-3 probe that is a 562 bp implantation growth and axial organization. Genes Dev. 8, 3045±
NcoI±EcoRI fragment from nucleotides 226±788 of the FGFR-3 3058.
cDNA (Ornitz and Leder, 1992).
Erlebacher, A., Filvaroff, E.H., Gitelman, S.E., and Derynck, R. (1995).
Toward a molecular understanding of skeletal development. Cell
In Situ Hybridization 80, 371±378.
The tissues to be analyzed were fixed in freshly prepared 4% para- Gilbert, S.F. (1994). Osteogenesis: The Development of Bones. De-
formaldehyde in phosphate-buffered saline for 4 hr at 48C and em- velopmental Biology, Fourth Ed. (Sunderland, MA: Sinauer Asso-
bedded in paraffin and sectioned at 6 mm. Slides with sections were ciates).
brought to room temperature, dewaxed, and hybridized to 35S-UTP-
Jacenko, O., LuValle, P.A., and Olsen, B.R. (1993). Spondylometa-labeled RNA probes for the Fgfr-1, Fgfr-2, and Fgfr-3 genes (see
physeal dysplasia in mice carrying a dominant negative mutation insection on Northern blots), the collagen type I, II, X, and XI (provided
a matrix protein specific for cartilage-to-bone transition. Nature365,by Bjorn Olsen) and BMP-2, BMP-4, and BMP-6 genes (provided
56±61.by Brigid L. M. Hogan) and incubated overnight in a humidified
Karaplis, A.C., Luz, A., Glowacki, J., Bronson, R.T., Tybulewicz, V.L.,box at 528C. The FGFR-1 probe is a 430 bp fragment including
Kronenberg, H.M., and Mulligan, R.C. (1994). Lethal skeletal dyspla-nucleotides 460±890, and the FGFR-2 is a 496 bp fragment including
sia from targeted disruption of the parathyroid hormone-relatednucleotides 380±876. Hybridization, washing, and RNase treatment
peptide gene. Genes Dev. 8, 277±289.followed the describedprocedure (Zeller et al., 1987) with the modifi-
cation that the labeled probes were not degraded. Slides were Kingsley, D.M., Bland, A.E., Grubber, J.M., Marker, P.C., Russell,
dipped in emulsion (Kodak NTB-2) and exposed for 4±15days before L.B., Copeland, N.G., and Jenkins, N.A. (1992). The mouse short ear
developing. skeletal morphogenesis locus is associated with defects in a bone
morphogenetic member of the TGFb superfamily. Cell 71, 399±410.
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